Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats

The modulation of melatonin signaling in peripheral tissues holds promise for treating metabolic ailments like weight problems, diabetes, and nonalcoholic steatohepatitis. Right here, a number of benzimidazole derivatives have been recognized as novel agonists of the melatonin receptors MT1 and MT2. The lead compounds <b>10b</b>, <b>15a</b>, and <b>19a</b> demonstrated subnanomolar efficiency at MT1/MT2 receptors, excessive

Read More